Mexicana Airlines Purchases Cardiac Science AEDs for Commercial Airliner Fleet
02 November 2004 - 5:30PM
PR Newswire (US)
Mexicana Airlines Purchases Cardiac Science AEDs for Commercial
Airliner Fleet IRVINE, Calif., Nov. 2 /PRNewswire-FirstCall/ --
Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of
life-saving automated public access defibrillators (AEDs) and
provider of comprehensive AED/CPR training services, today
announced that Mexicana Airlines has purchased 60 Powerheart(R) G3
AEDs for installation and use in their fleet of commercial
airliners. Mexicana joins other domestic and international airlines
that have deployed Cardiac Science AEDs including SkyWest Airlines,
Atlantic Coast Airlines, Japan Airlines, Japan Air Systems, Malev
Hungarian airlines and Saudi Arabian Airlines. Cardiac Science
Chairman and CEO Raymond W. Cohen said the life-saving AEDs are
being deployed on Mexicana national and international flights and
that passengers on flights with AEDs can rest assured that they are
well protected should they suffer sudden cardiac arrest. Mexicana
Airlines transports passengers between 53 destinations in North,
Central, South America, the Caribbean and Europe and is the
international airline leader for travel between the U.S. and
Mexico. About Cardiac Science Cardiac Science develops,
manufactures and markets Powerheart(R)-brand public-access
defibrillators (AEDs) and offers comprehensive AED/CPR training and
AED program management services that facilitate successful
deployments. Cardiac Science also manufactures its AED products on
a private label basis for other leading medical companies such as
Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare.
For more information, please visit http://www.cardiacscience.com/.
This news release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. In
addition, from time to time the company, or its representatives,
have made or may make forward looking statements orally or in
writing. The words "estimate," "potential," "intended," "expect,"
"anticipate," "believe," and other similar expressions or words are
intended to identify forward looking statements. Such
forward-looking statements include, but are not limited to the
achievement of future revenue growth and other expected financial
results. Cardiac Science cautions that these statements are subject
to substantial risks and uncertainties and are qualified by
important factors that could cause actual results to differ
materially from those reflected by the forward-looking statements
and should not be relied upon by investors when making an
investment decision. Information on these and other factors is
detailed in the company's Form 10-K for the year ended December 31,
2003, subsequent quarterly filings, and other documents filed by
the company with the Securities and Exchange Commission. For
further information please contact: Matt Clawson (Investors), , or
Len Hall (Media), , both of Allen & Caron Inc, +1-949-474-4300,
for Cardiac Science, Inc.; or Michael Gioffredi, Chief Marketing
Officer of Cardiac Science, Inc., +1-949-797-3800, DATASOURCE:
Cardiac Science, Inc. CONTACT: Matt Clawson (Investors), , or Len
Hall (Media), , both of Allen & Caron Inc, +1-949-474-4300, for
Cardiac Science, Inc.; or Michael Gioffredi, Chief Marketing
Officer of Cardiac Science, Inc., +1-949-797-3800, Web site:
http://www.cardiacscience.com/
Copyright
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jul 2023 to Jul 2024